LEADERSHIP TEAM
Gerben Moolhuizen
Gerben Moolhuizen, MBA, brings an impressive track record in drug development and a wealth of experience spanning over three decades across a diverse array of fields and technologies in the biopharmaceutical industry. Prior to joining 不良研究所, Gerben held several leadership positions in biotech and the pharmaceutical industry including Chief Executive Officer and Chief Business Officer at ISA Pharmaceuticals, General Manager at OctoPlus, which got acquired during his tenure by Dr. Reddy鈥檚 Laboratories Ltd. in 2013, and business development roles at Pharming Group. In these positions he was closely involved in all corporate development aspects across the biotech life cycle encompassing therapeutic product development, fundraising activities, IPO processes and acquisitions.
Gerben holds an M.Sc. from Utrecht University in Medical Biology and an MBA from Erasmus University Rotterdam.